StockNews.AI
GSK
StockNews.AI
33 days

US FDA Approves GSK's SHINGRIX in a Prefilled Syringe Presentation

1. FDA approves GSK's prefilled syringe for SHINGRIX, streamlining administration process.

FDA Approval
-5.22%Current Return
VS
+0.44%S&P 500
$38.2807/17 07:26 AM EDTEvent Start
$36.2807/18 01:53 PM EDTLatest Updated
2m saved
Insight
Article

FAQ

Why Bullish?

The approval enhances SHINGRIX's usability, potentially increasing sales. Past approvals in vaccine innovation have positively impacted GSK's stock.

How important is it?

The approval is likely to increase SHINGRIX adoption, positively affecting GSK's earnings.

Why Short Term?

The new presentation could boost sales quickly, leading to immediate revenue impact.

Related Companies

NVAXMRNAPFE
PHILADELPHIA--(BUSINESS WIRE)-- #Adult--GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved a prefilled syringe presentation of SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted) for the prevention of shingles (herpes zoster). The new prefilled syringe removes the need to reconstitute separate vials prior to administration, simplifying the vaccine administration process for healthcare professionals. The existing vaccine presentation consists of two vials, a.

Related News